DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
60	再生不良性貧血	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01623167 (ClinicalTrials.gov)	July 2, 2012	14/6/2012	Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia	Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia	Severe Aplastic Anemia	Drug: Cohort 1: hATG, CsA, EPAG Day 14 to Month 6;Drug: Cohort 2: hATG, CsA, EPAG Day 14 to Month 3;Drug: Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6;Drug: Extension Cohort	National Heart, Lung, and Blood Institute (NHLBI)	Novartis	Recruiting	2 Years	95 Years	All	207	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01623167
(ClinicalTrials.gov)

July 2, 2012

14/6/2012

Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia

Severe Aplastic Anemia

Drug: Cohort 1: hATG, CsA, EPAG Day 14 to Month 6;Drug: Cohort 2: hATG, CsA, EPAG Day 14 to Month 3;Drug: Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6;Drug: Extension Cohort

National Heart, Lung, and Blood Institute (NHLBI)

Novartis

Recruiting

2 Years

95 Years

All

207

Phase 1;Phase 2

United States